(Q53592484)

16 May 2018

title

The effects of FasL on inflammation and tumor survival are dependent on its expression levels. (English)

1 reference

16 May 2018

author name string

Wada A

1

1 reference

16 May 2018

Tada Y

2

1 reference

16 May 2018

Kawamura K

3

1 reference

16 May 2018

Takiguchi Y

4

1 reference

16 May 2018

Tatsumi K

5

1 reference

16 May 2018

Kuriyama T

6

1 reference

16 May 2018

Takenouchi T

7

1 reference

16 May 2018

O-Wang J

8

1 reference

16 May 2018

Tagawa M

9

1 reference

16 May 2018

publication date

20 October 2006

1 reference

16 May 2018

published in

Cancer Gene Therapy

1 reference

16 May 2018

volume

14

1 reference

16 May 2018

issue

3

1 reference

16 May 2018

page(s)

262-267

1 reference

16 May 2018

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7701008

exact match

0 references

cites work

Fas and Fas ligand: lpr and gld mutations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701008

Expression and function of Fas during differentiation and activation of B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701008

Induction of tolerance using Fas ligand: a double-edged immunomodulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701008

CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701008

Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701008

Presence of activin signal transduction in normal ovarian cells and epithelial ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701008

The Fas counterattack: cancer as a site of immune privilege

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701008

Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701008

Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701008

Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701008

Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701008

Countering the 'counterattack' hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701008

Altered antigen receptor signaling and impaired Fas-mediated apoptosis of B cells in Lyn-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701008

CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701008

Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701008

A role for CD95 ligand in preventing graft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701008

Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701008

7 January 2021

Prognostic relevance of altered Fas (CD95)-system in human breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701008

7 January 2021

The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701008

7 January 2021

Immune privilege or inflammation? Insights into the Fas ligand enigma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701008

7 January 2021

Antitumor effect of locally produced CD95 ligand

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701008

7 January 2021

Cutting edge: a novel role for Fas ligand in facilitating antigen acquisition by dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701008

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7701008

1 reference

16 May 2018

PubMed ID

17053813

1 reference

16 May 2018